arrow
N

Nobuhiro Tsukada

Japanese Red Cross Medical Center
H指数:24
被引数:4,155

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS

elranatamab在复发/难治性多发性骨髓瘤中的疗效:单核细胞计数、MyCARe和R2-ISS的预后影响

2025-12-010
PRE
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia in Japan

自体与异基因造血干细胞移植治疗日本原发性浆细胞白血病的比较

2025-09-080
PRE
Evaluation of Delayed Initiation of Lenalidomide Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

异基因造血干细胞移植后多发性骨髓瘤患者来那度胺维持治疗延迟启动的评估

2025-08-170
PRE
Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation

含奥氮强的强化止吐疗法在自体干细胞移植并接受高剂量美法仑治疗的多发性骨髓瘤患者中的疗效

2025-08-110
OAAI
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma

人巨细胞病毒视网膜炎发生在接受伊达克塔格韦利塞特(Idecabtagene vicleucel)治疗的患者中,这些患者患有复发/难治性多发性骨髓瘤。

2025-04-210
PRE
Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

真实世界经验:Isatuximab在复发和/或难治性多发性骨髓瘤(RRMM)患者中的应用——Iona-MM第二次中期分析

BLOOD
IF23.1
2024-11-051
PRE
Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma

自体造血细胞移植治疗侵袭性非霍奇金淋巴瘤和多发性骨髓瘤后血小板恢复延迟的不良影响

2023-11-013
OAAI
Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
2023-07-201
OAAI